DFH is working on development of the second generation HIV maturation inhibitor drugs. Current focus is on the pre-clinical assessment of the promising maturation inhibitor compounds identify ing drug candidates to advance into studies that will support the filing of an investigational new drug application with the FDA Initial efforts will spotlight on second generation compounds, DFH-055 and DFH-110, which have demonstrated potent activity against all HIV strains, including those that proved resistant to the first-in-class maturation inhibitor, bevirimat. New class of antiretroviral agents with a unique mechanism of action: maturation inhibitors.
